Sphingosine 1-phosphate chemical biology

Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids

Volumn 1781, Issue 9, 2008, Pages 508-512

  Lynch, Kevin R ^a   Macdonald, Timothy L ^b  

^a UNIVERSITY OF VIRGINIA   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Fingolimod; FTY720; S1P; S1P receptor; Sphingosine 1 phosphate; Sphingosine kinase; SPHK

Indexed keywords

CYCLOSPORIN; ENZYME INHIBITOR; FINGOLIMOD; N METHYL 5 (4' PENTYLPHENYL) 2 AMINOPENT 4 ENE 1,3 DIOL; SPHINGOSINE 1 PHOSPHATE; SPHINGOSINE 1 PHOSPHATE RECEPTOR; SPHINGOSINE KINASE INHIBITOR; TACROLIMUS; UNCLASSIFIED DRUG;

BIOCHEMISTRY; BRADYCARDIA; CLINICAL TRIAL; DYSPNEA; GRAFT REJECTION; HUMAN; KIDNEY GRAFT REJECTION; NONHUMAN; PRIORITY JOURNAL; RETINA MACULA EDEMA; REVIEW; SKIN GRAFT; TREATMENT FAILURE;

ANIMALS; BIOCHEMISTRY; ENZYME INHIBITORS; HUMANS; LYSOPHOSPHOLIPIDS; PROPYLENE GLYCOLS; RECEPTORS, LYSOSPHINGOLIPID; SPHINGOSINE;

EID: 51749114831     PISSN: 13881981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbalip.2008.06.006     Document Type: Review

References (67)

1. Kihara A., Mitsutake S., Mizutani Y., and Igarashi Y. Metabolism and biological functions of two phosphorylated sphingolipids, sphingosine 1-phosphate and ceramide 1-phosphate. Prog. Lipid. Res. 46 (2007) 126-144
2. Ancellin N., Colmont C., Su J., Li Q., Mittereder N., Chae S.S., Stefansson S., Liau G., and Hla T. Extracellular export of sphingosine kinase-1 enzyme. Sphingosine 1-phosphate generation and the induction of angiogenic vascular maturation. J. Biol. Chem. 277 (2002) 6667-6675
3. S.T. Pruett, A. Bushnev, K. Hagedorn, M. Adiga, C.A. Haynes, M.C. Sullards, D.C. Liotta, A.H. Merrill Jr., Sphingolipids. Biodiversity of sphingoid bases ("sphingosines") and related amino alcohols, J. Lipid Res. in press (21 May 2008) PMID: 18499644.
4. S. Bu, B. Kapanadze, T Hsu, M Trojanowska, Opposite effects of dihydrosphingosine 1-phosphate and sphingosine 1-phosphate on TGFbeta/Smad pathway are mediated through the PTEN/PPM1A dependent pathway, J. Biol. Chem. in press (15 May 2008) PMID: 18482992.
5. Venkataraman K., Lee Y.M., Michaud J., Thangada S., Ai Y., Bondovsky H.L., Parich N.S., Habrukowich C., and Hla T. Vascular endothelium as a contributor of plasma sphingosine 1-phosphate. Circ. Res. 102 (2008) 669-676
6. Allende M.L., Sasaki T., Kawai H., Olivera A., Mi T., van Echeten-Deckert G., Hajdu R., Rosenbach M., Keohane C.A., Mandala S., Spiegel S., and Proia R.L. Mice deficient in sphingosine kinase 1 are rendered lymphopenic by FTY720. J. Biol. Chem. 279 (2004) 52487-52492
7. Kharel Y., Lee S., Snyder A.H., Sheasley-O'Neill S.L., Morris M.A., Setiady Y., Zhu R., Zigler M.A., Burcin T.L., Ley K., Tung K.S.K., Engelhard V., Pearson-White S., Macdonald T.L., and Lynch K.R. Sphingosine kinase 2 is required for modulation of lymphocyte traffic by FTY720. J. Biol. Chem. 280 (2005) 36865-36872
8. Zemann B., Kinzel B., Müller M., Reuschel R., Mechtcheriakova D., Urtz N., Bornancin F., Baumruker T., and Billich A. Sphingosine kinase type 2 is essential for lymphodepletion induced by the immunomodulatory drug FTY720. Blood 107 (2006) 1454-1458
9. Mizugishi K., Li C., Olivera A., Bielawski J., Bielawska A., Deng C.X., and Proia R.L. Maternal disturbance in activated sphingolipid metabolism causes pregnancy loss in mice. J. Clin. Invest. 117 (2007) 2993-3006
10. Mechtcheriakova D., Wlachos A., Sobanov J., Bornancin R., Zlabinger G., Baumruker T., and Billich A. FTY720-phosphate is dephosphorylated by lipid phosphate phosphatase 3. FEBS Lett. 581 (2007) 3063-3068
11. Mandala S.M., Thornton R., Tu Z., Kurtz M.B., Nickels J., Broach J., Menzeleev R., and Spiegel S. Sphingoid base 1-phosphate phosphatase: a key regulator of sphingolipid metabolism and stress response. Proc. Natl. Acad. Sci. USA. 95 (1998) 150-155
12. Brinkmann V. Sphingosine 1-phosphate receptors in health and disease: mechanistic insights from gene deletions studies and reverse pharmacology. Pharmacol. Therap. 115 (2007) 85-104
13. Mandala S.M., Hajdu R., Bergstrom J., Quackenbush E., Xie J., Milligan J., Thornton R., Shei G.-j., Card D., Keohane C., Rosenbach M., Hale J., Lynch C.L., Rupprecht K., Parsons W., and Rosen H. Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science 296 (2002) 346-349
14. 4/Edg-6 receptor. Biochem. Biophys. Res. Comm. 297 (2002) 600-606
15. Spiegel S., and Milstein S. Exogenous and intracellularly generated sphingosine 1-phosphate can regulate cellular processes by divergent pathways. Biochem. Soc. Trans. 31 (2003) 1216-1219
16. Liu Y., Wada R., Yamashita T., Mi Y., Deng C.X., Hobson J.P., Rosenfeldt H.M., Nava V.E., Chae S.S., Lee M.J., Liu C.H., Hla T., Spiegel S., and Proia R.L. Edg-1, the G protein-coupled receptor for sphingosine-1-phosphate, is essential for vascular maturation. J. Clin. Invest. 106 (2000) 951-961
17. Allende M.L., Yamashita T., and Proia R.L. G-protein-coupled receptor S1P1 acts within endothelial cells to regulate vascular maturation. Blood 102 (2003) 3665-3667
18. MacLennan A.J., Carney P.R., Zhu W.J., Chaves A.H., Garcia J., Grimes J.R., Anderson K.J., Roper S.N., and Lee N. An essential role for the H218/AGR16/Edg-5/LP(B2) sphingosine 1-phosphate receptor in neuronal excitability. Eur. J. Neurosci. 14 (2001) 203-209
19. MacLennan A.J., Benner S.J., Andringa A., Chaves A.H., Rosing J.L., Vesey R., Karpman A.M., Cronier S.A., Lee N., Erway L.C., and Miller M.L. The S1P2 sphingosine 1-phosphate receptor is essential for auditory and vestibular function. Hearing. Res. 220 (2006) 38-48
20. Kono M., Belyantseva I.A., Sloura A., Frolenkov G.I., Starost M.F., Dreir J.L., Lidington D., Bolz S.S., Friedman R.B., Hla T., and Proia R.L. Deafness and stria vascularis defects in S1P2 receptor-null mice. J. Biol. Chem. 282 (2007) 10690-10696
21. Ishii I., Friedman B., Ye X., Kawamura S., McGiffert C., Contos J.J.A., Kingsbury M.A., Zhang G., Heller Brown J., and Chun J. Selective loss of sphingosine 1-phosphate signaling with no obvious phenotypic abnormality in mice lacking its G protein-coupled receptor. LP(B3)/EDG-3. J. Biol. Chem. 276 (2001) 33697-33704
22. Walzer T., Chiossone L., Chaix J., Calver A., Carozzo C., Garrigue-Antar L., Jacques Y., Baratin M., Tomasello E., and Viver E. Natural killer cell trafficking in vivo requires a dedicated sphingosine 1-phosphate receptor. Nature. Immunol. 8 (2007) 1337-1344
23. Im D.S. Linking Chinese medicine and G-protein coupled receptors. Trends. Pharmacol. Sci. 24 (2003) 2-4
24. Kiuchi M., Adachi K., Kohara T., Minoguchi M., Hanano T., Aoki Y., Mishina T., Arita M., Nakao N., Ohtsuki M., Hoshino Y., Teshima K., Chiba K., Sasaki S., and Fujita T. Synthesis and immunosuppressive activity of 2-substituted 2-aminopropane-1,3-diols and 2-aminoethanols. J. Med. Chem. 43 (2000) 2946-2961
25. Suzuki S., Li X.K., Enosawa S., and Shinomiya T. A new immunosuppressant, FTY720, induces bcl-2-associated apoptotic cell death in human lymphocytes. Immunology 89 (1996) 518-523
26. Brinkmann V., Davis M.D., Heise C.E., Albert R., Cottens S., Hof R., Bruns C., Prieschl E., Baumruker T., Hiestand P., Foster C., and Lynch K.R. The immune modulating drug, FTY720, and sphingosine 1-phosphate signaling. J. Biol. Chem. 277 (2002) 21453-21457
27. Paugh S.W., Payne S.G., Barbour S.E., Milstien S., and Spiegel S. The immunosuppressant FTY720 is phosphorylated by sphingosine kinase type 2. FEBS. Lett. 554 (2003) 189-193
28. Budge K., Schmouder R.L., Brukhorst R., Nashan B., Lucker P.W., Mayer T., Chouhury S., Skerjanec A., Kraus G., and Neumayer H.H. First human trial of FTY720 a novel immunomodulator, in stable renal transplant patients. J. Am. Soc. Nephrol. 13 (2002) 1073-1083
29. Forrest M., Sun S.Y., Hajdu R., Bergstrom J., Card D., Doherty G., Hale J., Keohane C., Meyers C., Milligan J., Mills S., Nomura N., Rosen H., Rosenbach M., Shei G.J., Singer I.I., Tian M., West S., White V., Xie J., Proia R.L., and Mandala S. Immune cell regulation and cardiovascular effects of S1P receptor agonists in rodents are mediated via distinct receptor sub-types. J. Pharmacol. Exp. Therap. 309 (2004) 758-768
30. Matloubian M., Lo C.G., Cinamon G., Lesneski M.J., Xu Y., Brinkmann V., Allende M.L., Proia R.L., and Cyster J.G. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature 427 (2004) 355-360
31. Allende M.L., Dreier J.L., Mandala S., and Proia R.L. Expression of the sphingosine 1-phosphate receptor, S1P1, on T-cells controls thymic emigration. J. Biol. Chem. 279 (2004) 15396-15401
32. Schwab S.R., Pereira J.P., Matloubian M., Xu Y., Huang Y., and Cyster J.G. Lymphocyte sequestration through S1P lyase inhibition and disruption of S1P gradients. Science 309 (2005) 1735-1739
33. Wei S.H., Rosen H., Matheu M.P., Sanna M.G., Wang S.K., Jo E., Wong C.H., Parker I., and Cahalan M.D. Sphingosine 1-phosphate type 1 receptor agonism inhibits transendothelial migration of medullary T cells to lymphatic sinuses. Nature. Immunol. 6 (2005) 1228-1235
34. Schwab S.R., and Cyster J.G. Finding a way out: lymphocyte egress from lymphoid organs. Nature. Immunol. 8 (2007) 1295-1301
35. Rosen H., Sanna M.G., Cahalan S.M., and Gonzalez-Cabrera P.J. Tipping the gatekeeper: S1P regulation of endothelial barrier function. Trends. Immunol. 28 (2007) 102-107
36. Tedesco-Silva H., Szakaly P., Shoker A., Sommerer C., Yoshimura N., Schena F.P., Cremer M., Hmissi A., Mayer H., Lang P., and FTY720 2218 Clinical Study Group. FTY720 versus mycophenolate mofetil in de novo renal transplantation: six-month results of a double-blind study. Transplantation 84 (2007) 885-892
37. Oppenheimer F., Mulgaonkar S., Fergusan R., Grinyo J., Juarez F., Ostrowski M., Klinger M., Walker R., Torres A., Preiss R., Cremer M., Jardine A., and FTY720 2216 Clinical Study Group. Impact of long-term therapy with FTY720 or mycophenolate mofetil on cardiac conduction and rhythm in stable adult renal transplant patients. Transplantation 83 (2007) 645-648
38. Kappos L., Antel J., Comi G., Montalban X., O'Connor P., Polman C.H., Haas T., Korn S.S., Karlsson G., and E.W. Radue for the FTY720 D2201 Study Group. Oral fingolimod (FTY720) for relapsing multiple sclerosis. New Eng. J. Med. 355 (2006) 1124-1140
39. Sanna M.G., Liao J., Jo E., Alfonso C., Ahn M.-Y., Peterson M.S., Webb B., Lefebvre S., Chun J., Gray N., and Rosen H. Sphingosine 1-phosphate receptor subtypes S1P1 and S1P3, respectively, regulated lymphocyte recirculation and heart rate. J. Biol. Chem. 279 (2004) 13839-13848
40. LaMontagne K., Littlewood-Evans A., Schnell C., O'Reilly T., Wyder L., Sanchez T., Probst B., Butler J., Wood A., Liau G., Billy E., Theuer A., Hla T., and Wood J. Antagonism of sphingosine 1-phosphate receptors by FTY720 inhibits angiogenesis and tumor vascularization. Cancer Res. 66 (2006) 221-231
41. Nofer J.R., Bot M., Brodde M., Taylor P.J., Salm P., Brinkmann V., van Berkel T., Assmann G., and Biessen E.A. FTY720, a synthetic sphingosine 1 phosphate analogue, inhibits development of atherosclerosis in low-density lipoprotein receptor-deficient mice. Cell Mol. Immunol. 3 (2006) 429-437
42. Awad A.S., Ye H., Huang L., Li L., Foss, Jr. F.W., Macdonald T.L., Lynch K.R., and Okusa M.D. Selective sphingosine 1-phosphate 1 receptor activation reduces ischemia-reperfusion injury in mouse kidney. Am. J. Physiol. 290 (2006) F1516-F1524
43. Lien Y.H., Yong K.C., Cho C., Igarashi S., and Lai L.W. S1P(1)-selective agonist, SEW2871, ameliorates ischemic acute renal failure. Kidney Int. 69 (2006) 1601-1608
44. Delbridge M.S., Shrestha B.M., Raftery A.T., El Nahas A.M., and Haylor J.L. Reduction of ischemia-reperfusion injury in the rat kidney by FTY720, a synthetic derivative of sphingosine. Transplantation 84 (2007) 187-195
45. Coste O., Pierre S., Marian C., Brenneis C., Angioni C., Schmidt H., Popp L., Geisslinger G., and Scholich K. Antinociceptive activity of the S1P receptor agonist FTY720. J. Cell Mol. Med. (2007) Electronic publication ahead of print
46. Schmid G., Guba M., Ischenko I., Papyan A., Joka M., Schrepfer S., Bruns C.J., Jauch K.W., Heeschen C., and Graeb C. The immunosuppressant FTY720 inhibits tumor angiogenesis via the sphingosine 1-phosphate receptor 1. J. Cell Biochem. 101 (2007) 259-270
47. Peng X., Hassoun P.M., Sammani S., McVerry B.J., Burne M.J., Rabb H., Pearse D., Tuder R.M., and Garcia J.G. Protective effects of sphingosine 1-phosphate in murine endotoxin-induced inflammatory lung injury. Am. J. Respir. Crit. Care Med. 169 (2004) 1245-1251
48. Paugh S.W., Cassidy M.P., He H., Milstein S., Sim-Selley L.J., Spiegel S., and Selley D.E. Sphingosine and its analog, the immunosuppressant 2-amino-2-(2-[4-octylphenyl]ethyl)-1,3-propanediol, interact with the CB1 cannabinoid receptor. Mol. Pharmacol. 70 (2006) 41-50
49. Neviani P., Santhanam R., Oaks J.J., Eiring A.M., Notari M., Blaser B.W., Liu S., Trotta R., Muthusamy N., Gambacorti-Passerini C., Druker B.J., Cortes J., Marcucci G., Chen C.S., Verrills N.M., Roy D.C., Caligiuri M.A., Bloomfield C.D., Byrd J.C., and Perrotti D. FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia. J. Clin. Invest. 117 (2007) 2408-2421
50. Pan S., Mi Y., Pally C., Beerli C., Chen A., Guerini D., Hinterding K., Nuesslein-Hildesheim B., Tuntland T., Lefebvre S., Liu Y., Gao W., Chu A., Brinkmann V., Bruns C., Streiff M., Cannet C., Cooke N., and Gray N. A monoselective sphingosine-1-phosphate receptor-1 agonist prevents allograft rejection in a stringent rat heart transplantation model. Chem. Biol. 13 (2006) 1227-1234
51. Jo E., Sanna M.G., Gonzalez-Cabrera P.J., Thangada S., Tigyi G., Osborne D.A., Hla T., Parrill A.L., and Rosen H. S1P1-selective in vivo-active agonists from high-throughput screening: off-the-shelf chemical probes of receptor interactions, signaling, and fate. Chem. Biol. 12 (2005) 703-715
52. 3. J. Med. Chem. 48 (2005) 6169-6173
53. Hanessian S., Charron G., Billich A., and Guerini D. Constrained azacyclic analogues of the immunomodulatory agent FTY720 as molecular probes for sphingosine 1-phosphate receptors. Bioorg. Med. Chem. Lett. 17 (2006) 491-494
54. Albert R., Hinterding K., Brinkmann V., Guerini D., Müller-Hartwieg C., Knecht H., Simeon C., Streiff M., Wagner T., Welzenbach K., Zécri F., Zollinger F.M., Cooke N., and Francotte E. Novel immunomodulator FTY720 is phosphorylated in rats and humans to form a single stereoisomer. Identification, chemical proof, and biological characterization of the biologically active species and its enantiomer. J. Med. Chem. 48 (2005) 5373-5377
55. Zhu R., Snyder A.H., Kharel Y., Schaffter L., Sun Q., Kennedy P.C., Lynch K.R., and Macdonald T.L. Asymmetric synthesis of conformationally constrained fingolimod analogues - discovery of an orally active sphingosine 1-phosphate receptor type-1 agonist and receptor type-3 antagonist. J. Med. Chem. 13 (2007) 6428-6435
56. Davis M.D., Clemens J.J., Macdonald T.L., and Lynch K.R. Sphingosine 1-phosphate analogs as receptor antagonists. J. Biol. Chem. 280 (2005) 9833-9841
57. Sanna M.G., Wang S.K., Gonzalez-Cabrera P.J., Don A., Marsolais D., Matheu M.P., and Rosen H. Enhancement of capillary leakage and restoration of lymphocyte egress by a chiral S1P1 agonist in vivo. Nature. Chem. Biol. 2 (2006) 431-441
58. Foss, Jr. F.W., Snyder A.H., Davis M.D., Rouse M., Okusa M.D., Lynch K.R., and Macdonald T.L. Synthesis and biological evaluation of gamma-aminophosphonates as potent, subtype-selective sphingosine 1-phosphate receptor agonists and antagonists. Bioorg. Med. Chem. 15 (2007) 663-667
59. B. Wamhoff, K.R. Lynch, T.L. Macdonald, G.K. Owens, Sphingosine-1-phosphate receptor subtypes differentially regulate smooth muscle cell phenotype, Arteriosclerosis, Thromb. Vascular Biol. in press, (5 June 2008) PMID: 18535287.
60. Ikeda H., Satoh H., Yanase M., Inoue Y., Tomiya T., Arai M., Tejima K., Nagashima K., Maekawa H., Yahagi N., Yatomi Y., Sakurada S., Takuwa Y., Ogata I., Kimura S., and Fujiwara K. Antiproliferative property of sphingosine 1-phosphate in rat hepatocytes involves activation of Rho via Edg-5. Gastroenterology 124 (2003) 459-469
61. Skoura A., Sanchez T., Claffey K., Mandala S.M., Proia R.L., and Hla T. Essential role of sphingosine 1-phosphate receptor 2 in pathological angiogenesis of the mouse retina. J. Clin. Invest. 117 (2007) 2506-2516
62. Visentin B., Vekich J.A., Sibbald B.J., Cavalli A.L., Moreno K.M., Matteo R.G., Garland W.A., Lu Y., Yu S., Hall H.S., Kundra V., Mills G.B., and Sabbadini R.A. Validation of an anti-sphingosine-1-phosphate antibody as a potential therapeutic in reducing growth, invasion, and angiogenesis in multiple tumor lineages. Cancer Cell 9 (2006) 225-238
63. Liu H., Sugiura M., Nava V.E., Edsall L.C., Kono K., Poulton S., Milstein S., Kohama T., and Spiegel S. Molecular cloning and functional characterization of a novel mammalian sphingosine kinase type 2 isoform. J. Biol. Chem. 275 (2000) 19513-19520
64. French K.J., Upson J.J., Keller S.N., Zhuang Y., Yun J.K., and Smith C.D. Antitumor activity of sphingosine kinase inhibitors. J. Pharmacol. Exp. Therap. 318 (2006) 596-603
65. Kim J.-W., Kim Y.-W., Inagaki Y., Hwang Y.-A., Mitsutake S., Ryu Y.-W., Lee W.K., Ha H.-J., Park C.-S., and Igarashi Y. Synthesis and evaluation of sphingoid analogs as inhibitors of sphingosine bases. Bioorg. Med. Chem. 13 (2005) 3475-3485
66. S.W. Paugh, B.S. Paugh, M. Rahmani, D. Kapitonov, J.A. Almenara, T. Kordula, S. Milstien, J.K. Adams, R.E. Zipkin, S. Grant, S. Spiegel, A selective sphingosine kinase 1 inhibitor integrates multiple molecular therapeutic targets in human leukemia, Blood in press (29 May 208) doi: 10.1182/blood-2008-02-138958.
67. Jo S.-K., Bajwa A., Awad A.S., Lynch K.R., and Okusa M.D. Sphingosine-1-phosphate receptors: biology and therapeutic potential in kidney disease. Kidney. Int. 73 (2008) 1176-1186